Entera Bio appoints Organon executive Juan Camilo Arjona Ferreira to board
Entera Bio's board appointed Dr. Juan Camilo Arjona Ferreira, Head of R&D and Chief Medical Officer at Organon, as a Class II director effective December 1, 2026, and he will join the compensation committee. Director Haya Taitel is stepping down from the board on the same date, and the filing says her departure was not due to any disagreement with the company.
Key points
- Dr. Arjona Ferreira is the Head of R&D and Chief Medical Officer at Organon & Co. (NYSE: OGN) and previously held roles at Myovant Sciences, Shionogi and Merck & Co.
- Board appointment is effective December 1, 2026, and he will serve until the 2027 Annual Meeting of Shareholders.
- Haya Taitel notified the board on October 27, 2026 that she will step down as a director effective December 1, 2026.
- The board determined Dr. Arjona Ferreira is independent under SEC and Nasdaq rules.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.